HUBBARD, Ohio, Sept. 17 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC:NNLX), a nano-biotechnology company, announced it has achieved a historical event with the first onsite generation of electricity using hydrogen gas produced from its bioreactor prototype facility at Welch Foods Inc., a Cooperative in Pennsylvania. A 5.5 kW generator converted to run on hydrogen was utilized for the demonstration. The generator ran flawlessly on hydrogen gas produced by NanoLogix's hydrogen bioreactor system and powered multiple strings of 100- watt light bulbs. "To the best of our knowledge, this is the first time in history that electricity has been generated anywhere onsite using hydrogen produced through the use of bacteria to digest waste", said Harry Diz, Department Chair and Professor of Environmental Engineering at Gannon University and NanoLogix Bioreactor Development chief. Paul Zorzie, Welch's Engineering Manager, stated, "Welch's is happy to provide the site at which this groundbreaking research into generating alternative energy from waste is taking place. We look forward to the potential of building upon these developments to scale up and use this energy for our operation." Bret Barnhizer, Chairman and CEO of NanoLogix, stated, "We are delighted at the results of the work by Professor Diz and associates and anticipate potential upscaling of the Welch's operation to commercial bioreactor status. The Welch's development, enabling conversion of sugar from their wastewater stream to produce hydrogen, has contributed immeasurably to ongoing research and development for processing other types of waste streams. Linked to that development and following our business plan for expansion, in the spring of 2008 we intend to begin bioreactor construction at the Erie Wastewater Treatment Plant for the extraction of hydrogen from their protein-rich activated sludge waste stream." About NanoLogix, Inc. NanoLogix is a leading innovator in the research, development, and commercialization of nano-biotechnologies, applications and processes. The Company has 31 granted Patents and 36 Patents Pending for bioreactor-based hydrogen production, revolutionary rapid medical testing technologies, potential treatments for sepsis and cancer, and bioremediation. Information on NanoLogix is available at http://www.nanologixinc.com/. This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results. Contact: Investor Relations Bret Barnhizer, CEO Telephone: 330-534-0800 E-mail: DATASOURCE: NanoLogix Inc. CONTACT: Investor Relations, Bret Barnhizer, CEO of NanoLogix, Inc., +1-330-534-0800, Web site: http://www.nanologixinc.com/

Copyright